The genetic landscape of classical myeloproliferative neoplasm (MPN) is in large part
elucidated. The MPN-restricted driver mutations, including those in JAK2, calreticulin …

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is
central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane …

Background Approximately 50 to 60% of patients with essential thrombocythemia or primary
myelofibrosis carry a mutation in the Janus kinase 2 gene (JAK2), and an additional 5 to …

Myelodysplastic syndromes (MDS) are a heterogeneous group of chronic hematological
malignancies characterized by dysplasia, ineffective hematopoiesis and a variable risk of …

Patient outcome in primary myelofibrosis (PMF) is significantly influenced by karyotype. We
studied 879 PMF patients to determine the individual and combinatorial prognostic …

Background Myelodysplastic syndromes are clinically heterogeneous disorders
characterized by clonal hematopoiesis, impaired differentiation, peripheral-blood …

Background Myelodysplastic syndromes are a diverse and common group of chronic
hematologic cancers. The identification of new genetic lesions could facilitate new …

Abnormalities of chromosome 7q are common in myeloid malignancies, but no specific
target genes have yet been identified. Here, we describe the finding of homozygous EZH2 …

Essential thrombocythemia (ET) and primary myelofibrosis (PMF) are chronic diseases
characterized by clonal hematopoiesis and hyperproliferation of terminally differentiated …

Somatic mutations in calreticulin (CALR) are present in approximately 40% of patients with
myeloproliferative neoplasms (MPN), but the mechanism by which mutant CALR is …